Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed malignancy of a type typically associated with Epstein-Barr
virus (EBV) latent infection meeting the following criteria:

- The presence of EBV within the malignant cells has been demonstrated by
immunohistochemistry for viral antigens or by EBER (EBV early RNA) in situ
hybridization

- Patients in remission from disease or with disease for which no standard treatment is
appropriate, as defined by 1 of the following groups:

- Have achieved a continuing complete response (CR) or unconfirmed CR

- Residual masses at the site of treated disease that are not progressing (i.e.,
stable disease) and for which no standard therapy is recognized

- Residual or recurrent disease that is low-volume and causing minimal or no
symptoms and for which no standard therapy is recognized

- Completed standard therapy for malignancy ≥ 12 weeks before trial entry

- No more than 1 course of chemotherapy as treatment for EBV+ malignancy

- No ongoing toxic manifestations of prior treatment, except alopecia or certain grade
1 toxicities at the discretion of the investigator and Cancer Research UK

- No patients with active EBV+ cancer for whom evidence-based active treatment is
available and likely to be offered to prolong life or relieve symptoms within 14
weeks of the first vaccination

PATIENT CHARACTERISTICS:

- WHO performance status 0 or 1

- Life expectancy ≥ 4 months

- Lymphocyte count must satisfy 1 of the following criteria:

- Greater than lower limit of the reference range in the investigator site

- Greater than or equal to 0.5 x 10^9/L AND recovery from nadir of lymphocyte
numbers following primary treatment for EBV+ malignancy, judged by no successive
rises in lymphocyte count measured up to 3 successive occasions 3 weeks apart

- Hemoglobin > 10.0 g/dL

- Absolute neutrophil count ≥ 1.5 x 10^9/L

- Platelet count ≥ 100 x 10^9/L

- Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

- Serum alkaline phosphatase < 1.5 times ULN

- ALT and/or AST < 1.5 times ULN

- Calculated creatinine clearance > 50 mL/min (uncorrected value) OR isotope clearance
measurement > 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during study and for 6 months after
completion of study treatment

- No known chronic active infection with hepatitis B, hepatitis C, or HIV

- No history of anaphylaxis or severe allergy to vaccinations

- No allergy to eggs or egg products

- No ongoing active infection

- No known splenic dysfunction

- No concurrent active autoimmune disease

- No prior NYHA class III or IV cardiac disease or concurrent congestive heart failure

- No concurrent active skin diseases requiring therapy (i.e., psoriasis, eczema)

- No other condition that, in the Investigator's opinion, would make the patient not a
good candidate for this clinical trial

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior myeloablative therapy followed by an autologous or allogeneic hematopoietic
stem cell transplant

- More than 12 weeks since prior and no concurrent chemotherapy or radiotherapy

- No splenectomy or splenic irradiation

- No concurrent immunosuppressive medication, including corticosteroids

- Long-term prophylactic use of inhaled corticosteroids allowed

- No major thoracic and/or abdominal surgery within the past 4 weeks from which the
patient has not yet recovered

- No other concurrent anticancer or investigational drugs